<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>BioWorld Science</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors</title>
      <description>
        <![CDATA[Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors potentially useful for the treatment of cancer, pain, fibrosis and inflammatory disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731753</guid>
      <pubDate>Mon, 08 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731753-empire-discovery-institute-univ-of-rochester-identify-irak-inhibitors</link>
    </item>
    <item>
      <title>Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors</title>
      <description>
        <![CDATA[Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731752</guid>
      <pubDate>Mon, 08 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731752-antares-therapeutics-divulges-new-cdk2-cyclin-e1-inhibitors</link>
    </item>
    <item>
      <title>Eikon Therapeutics discloses new USP1 inhibitors</title>
      <description>
        <![CDATA[Eikon Therapeutics Inc. has disclosed new ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731751</guid>
      <pubDate>Mon, 08 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731751-eikon-therapeutics-discloses-new-usp1-inhibitors</link>
    </item>
    <item>
      <title>U.S. researchers report new antimalarial compounds</title>
      <description>
        <![CDATA[Brown University, Florida Atlantic University and Florida International University have jointly identified new compounds potentially useful for the treatment of malaria.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731750</guid>
      <pubDate>Mon, 08 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731750-us-researchers-report-new-antimalarial-compounds</link>
    </item>
    <item>
      <title>Onkure Therapeutics patents new PI3Kα mutant inhibitors</title>
      <description>
        <![CDATA[Onkure Therapeutics Inc. has disclosed new benzopyridinones acting as phosphatidylinositol 3-kinase α (PI3Kα) mutant inhibitors potentially useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities, scoliosis and PIK3CA-related overgrowth spectrum (PROS).]]>
      </description>
      <guid>http://www.bioworld.com/articles/731749</guid>
      <pubDate>Mon, 08 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731749-onkure-therapeutics-patents-new-pi3k-mutant-inhibitors</link>
    </item>
    <item>
      <title>Dual ABCB4/ABCB11 modulation shows promise in cholestatic disease models</title>
      <description>
        <![CDATA[Researchers from Rectify Pharmaceuticals Inc. presented preclinical efficacy data on RTY-406, a novel dual-acting ABCB4/MDR3 and ABCB11/BSEP modulator, in animal models of primary sclerosing cholangitis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731744</guid>
      <pubDate>Mon, 08 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731744-dual-abcb4-abcb11-modulation-shows-promise-in-cholestatic-disease-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-gallbladder-bile-ducts-anatomy.webp?t=1669131393" type="image/png" medium="image" fileSize="718435">
        <media:title type="plain">Liver anatomy illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>LBL-051: Broad immune targeting in autoimmune disease </title>
      <description>
        <![CDATA[Researchers at Obleno Bio Inc. have reported preclinical efficacy data for LBL-051-S3, a trispecific T-cell engager antibody targeting CD3, CD19 and BCMA, in nonhuman primate models.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731743</guid>
      <pubDate>Mon, 08 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731743-lbl-051-broad-immune-targeting-in-autoimmune-disease</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Antibodies-research-discovery-immune.webp?t=1772641847" type="image/jpeg" medium="image" fileSize="240482">
        <media:title type="plain">Illustration of magnifying glass and antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>ATG-207 shows efficacy in EAE with reduced cytokine release</title>
      <description>
        <![CDATA[At the recent European Congress of Rheumatology (EULAR) meeting in London, researchers from Antegene Corp. Ltd. presented the preclinical characterization of ATG-207, an αCD3-TGF-β bifunctional fusion protein, in models of T-cell-driven autoimmune disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731742</guid>
      <pubDate>Mon, 08 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731742-atg-207-shows-efficacy-in-eae-with-reduced-cytokine-release</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Lymphocyte-tcell-bcell.webp?t=1726498696" type="image/jpeg" medium="image" fileSize="222409">
        <media:title type="plain">Illustration of lymphocytes</media:title>
      </media:content>
    </item>
    <item>
      <title>China’s NMPA clears Hansoh’s HS-10541 for clinic</title>
      <description>
        <![CDATA[Hansoh Pharmaceutical Group Co. Ltd. has obtained clinical trial approval from China’s National Medical Products Administration (NMPA) for HS-10541 tablets.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731741</guid>
      <pubDate>Mon, 08 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731741-chinas-nmpa-clears-hansohs-hs-10541-for-clinic</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-tumor-blood-supply-vessels.webp?t=1683902294" type="image/jpeg" medium="image" fileSize="254242">
        <media:title type="plain">Art concept for tumor</media:title>
      </media:content>
    </item>
    <item>
      <title>Genescience presents data on Gensci-136, a dual BAFF/APRIL inhibitor for SLE</title>
      <description>
        <![CDATA[Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder characterized by dysregulation in humoral immunity and sustained activation of B cells and autoantibody release, where BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand) play crucial roles in B-cell differentiation and survival. Genescience Pharmaceutical Co. Ltd. has released data for its dual BAFF and APRIL inhibitor Gensci-136 for the treatment of SLE.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731740</guid>
      <pubDate>Mon, 08 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731740-genescience-presents-data-on-gensci-136-a-dual-baff-april-inhibitor-for-sle</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/B-cell-releasing-antibodies.webp?t=1720105710" type="image/jpeg" medium="image" fileSize="122329">
        <media:title type="plain">B-cell releasing antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>Amphista’s BRD9 degrader gains IND clearance for AML</title>
      <description>
        <![CDATA[Amphista Therapeutics Ltd. has obtained IND clearance from the FDA for AMX-883, an orally bioavailable degrader of BRD9, for the treatment of acute myeloid leukemia (AML). A phase I trial in patients with relapsed or refractory AML and high-risk myelodysplastic syndrome is expected to begin in the second half of this year.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731739</guid>
      <pubDate>Mon, 08 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731739-amphistas-brd9-degrader-gains-ind-clearance-for-aml</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/AML-Acute-Myekoid-Leukemia-Cells.webp?t=1718809128" type="image/jpeg" medium="image" fileSize="305580">
        <media:title type="plain">3D illustration of acute myeloid leukemia cells</media:title>
      </media:content>
    </item>
    <item>
      <title>CD39 mRNA-loaded nanoliposomes attenuate local acute inflammation</title>
      <description>
        <![CDATA[CD39, also known as ectonucleoside triphosphate diphosphohydrolase-1 (ENTPD1), is a cell surface ectonucleotidase with key roles in modulating inflammation and localized immune regulation. Researchers from the Baker Heart and Diabetes Institute and collaborators recently proposed leveraging mRNA technologies to provide sustained, localized CD39 expression without genomic integration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731738</guid>
      <pubDate>Mon, 08 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731738-cd39-mrna-loaded-nanoliposomes-attenuate-local-acute-inflammation</link>
    </item>
    <item>
      <title>Skape Bio unlocks GPCR targets with de novo-designed miniproteins</title>
      <description>
        <![CDATA[Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The scientific community has explored small molecules, antibodies and nanobodies to develop ligands. Skape Bio Inc. is betting on creating miniproteins, a strategy that brings precise solutions for different functions.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731737</guid>
      <pubDate>Mon, 08 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731737-skape-bio-unlocks-gpcr-targets-with-de-novo-designed-miniproteins</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/Beta2-Adrenergic-receptor-GPCR-protein-molecule.webp?t=1780929969" type="image/jpeg" medium="image" fileSize="676137">
        <media:title type="plain">3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.</media:title>
        <media:description type="plain">β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.</media:description>
      </media:content>
    </item>
    <item>
      <title>NME Digest: Q1 2026</title>
      <description>
        <![CDATA[A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications during the quarter.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731756</guid>
      <pubDate>Fri, 05 Jun 2026 10:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731756-nme-digest-q1-2026</link>
    </item>
    <item>
      <title>Technique links non-coding mutations to disease genes they regulate</title>
      <description>
        <![CDATA[Genome-wide association studies (GWAS) have identified multiple loci associated with complex diseases, but these are mostly on regulatory genes in the non-coding part of the genome and it has proved difficult to identify the effector genes that they control. Now, researchers in the U.K. have shown how single cell sequencing at scale can be used to precisely link non-coding GWAS loci to specific protein coding genes and cell types.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731755</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731755-technique-links-non-coding-mutations-to-disease-genes-they-regulate</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/GI-system-with-DNA-scientific-background.webp?t=1774388477" type="image/jpeg" medium="image" fileSize="500606">
        <media:title type="plain">Gastrointestinal system with DNA, scientific background</media:title>
      </media:content>
    </item>
    <item>
      <title>Simcere Zaiming Pharmaceutical discovers new MAPK inhibitors</title>
      <description>
        <![CDATA[Simcere Zaiming Pharmaceutical Co. Ltd. has divulged new mitogen-activated protein kinase (MAPK) inhibitors found to be potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731687</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731687-simcere-zaiming-pharmaceutical-discovers-new-mapk-inhibitors</link>
    </item>
    <item>
      <title>Avelos Therapeutics synthesizes new PARG inhibitors</title>
      <description>
        <![CDATA[Avelos Therapeutics Inc. has identified new poly(ADP-ribose) glycohydrolase (PARG) inhibitors that are potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731686</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731686-avelos-therapeutics-synthesizes-new-parg-inhibitors</link>
    </item>
    <item>
      <title>New York University identifies new analogues of mannose-6-phosphate</title>
      <description>
        <![CDATA[New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment, neurodegeneration and neurodevelopmental disorders, among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731685</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731685-new-york-university-identifies-new-analogues-of-mannose-6-phosphate</link>
    </item>
    <item>
      <title>Hengrui Pharmaceutical divulges new VAV1 degradation inducers</title>
      <description>
        <![CDATA[Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have reported molecular glue degraders acting as proto-oncogene Vav (VAV1) degradation inducers found to be potentially useful for the treatment of cancer, inflammatory disorders and autoimmune diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731684</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731684-hengrui-pharmaceutical-divulges-new-vav1-degradation-inducers</link>
    </item>
    <item>
      <title>Sichuan Kelun-Biotech patents new anthracyclins</title>
      <description>
        <![CDATA[Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has disclosed new anthracyclins that are useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731683</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731683-sichuan-kelun-biotech-patents-new-anthracyclins</link>
    </item>
    <item>
      <title>Seed funding at Artan Bio supports work on aging</title>
      <description>
        <![CDATA[Artan Biotechnologies LLC has completed a $200,000 seed raise to fund preclinical advancement of the company’s proprietary engineered suppressor platform, which targets nonsense mutations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731677</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731677-seed-funding-at-artan-bio-supports-work-on-aging</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Aging-and-molecules-concept-art.webp?t=1749159445" type="image/jpeg" medium="image" fileSize="936470">
        <media:title type="plain">Woman and molecular overlay</media:title>
      </media:content>
    </item>
    <item>
      <title>Lipopolyplex-delivered, DISE-inducing small RNAs as broad-spectrum anticancer therapy</title>
      <description>
        <![CDATA[Previous work found that certain short RNAs can induce cell death in a RISC-dependent fashion by targeting several networks of survival genes simultaneously, therefore triggering multiple cell death pathways. This form of cell death was named death induced by survival gene elimination, or DISE, an effect that depends on a toxic 6-mer seed.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731676</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731676-lipopolyplex-delivered-dise-inducing-small-rnas-as-broad-spectrum-anticancer-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Targeted-cancer-cell.webp?t=1741213881" type="image/jpeg" medium="image" fileSize="269059">
        <media:title type="plain">Targeted cancer cell</media:title>
      </media:content>
    </item>
    <item>
      <title>AxS007 penetrates BBB for breast cancer brain metastases</title>
      <description>
        <![CDATA[About 90% of brain metastases are often limited therapeutically speaking due to the impermeable blood-brain barrier (BBB). Nanocarry Therapeutics Ltd. has presented AxS007, a novel insulin-mediated nanocarrier that delivers multiple copies of trastuzumab and pertuzumab across the BBB, using native insulin as a brain transporter and increasing brain exposure.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731675</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731675-axs007-penetrates-bbb-for-breast-cancer-brain-metastases</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Blood-Brain-Barrier-Illustration.webp?t=1678203491" type="image/png" medium="image" fileSize="856287">
        <media:title type="plain">Illustration of brain in head highlighting the blood-brain barier.</media:title>
      </media:content>
    </item>
    <item>
      <title>Preclinical evaluation of a CAIX-targeted PET tracer</title>
      <description>
        <![CDATA[The University of Texas MD Anderson Cancer Center reported findings from studies of CBT-001-2334, a radionuclide peptide targeting carbonic anhydrase IX (CAIX/CA9) designed for diagnostic gallium labeling and downstream therapeutic isotope pairing. It features a DOTA chelator for use in theranostic applications through chelating either diagnostic or therapeutic radionuclides. Because it has limited expression in normal tissue, CAIX is an attractive target in clear cell renal cell carcinoma (ccRCC).]]>
      </description>
      <guid>http://www.bioworld.com/articles/731674</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731674-preclinical-evaluation-of-a-caix-targeted-pet-tracer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Open-blue-capsule-with-yellow-radioactive-symbol.webp?t=1776106225" type="image/jpeg" medium="image" fileSize="149663">
        <media:title type="plain">Open blue capsule with yellow radioactive symbol</media:title>
      </media:content>
    </item>
    <item>
      <title>Arvinas joins MJFF initiatives to advance LRRK2 research</title>
      <description>
        <![CDATA[Arvinas Inc. has joined the LRRK2 Investigative Therapeutics Exchange (LITE) program and the Parkinson’s Precision Medicine Initiative (PPMI), both supported by The Michael J. Fox Foundation for Parkinson’s Research (MJFF).]]>
      </description>
      <guid>http://www.bioworld.com/articles/731673</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731673-arvinas-joins-mjff-initiatives-to-advance-lrrk2-research</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Neurology-brain-target-bullseye-precision-magnifying-glass.webp?t=1773432347" type="image/jpeg" medium="image" fileSize="305403">
        <media:title type="plain">Art concept for targeting the brain</media:title>
      </media:content>
    </item>
    <item>
      <title>Pfizer’s integrin β6 ADC advances intravesical therapy for NMIBC</title>
      <description>
        <![CDATA[Researchers from Pfizer reported preclinical efficacy of PF-08052667, an antibody-drug conjugate (ADC) targeting integrin β6 (ITGB6), in non-muscle-invasive bladder cancer (NMIBC) models.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731672</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731672-pfizers-integrin-6-adc-advances-intravesical-therapy-for-nmibc</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/ADC-antibody-drug-conjugate-green.webp?t=1706306980" type="image/jpeg" medium="image" fileSize="182154">
        <media:title type="plain">3D rendering of drug linked to antibody</media:title>
      </media:content>
    </item>
    <item>
      <title>TRIM21 marks viruses and bacteria for degradation via autophagy</title>
      <description>
        <![CDATA[TRIM21, an enzyme involved in intracellular substrate degradation, can recognize viruses and bacteria that enter the cytosol when they are coated with antibodies. Just as it tags complex molecules for elimination, it can direct these infectious microorganisms to lysosomes through a mechanism its discoverers have termed antibody-directed xenophagy (ADX). Scientists at the Medical Research Council (MRC) Laboratory of Molecular Biology (LMB) in Cambridge, U.K., have identified the genes involved in this antibody-dependent degradation pathway, which acts as an antimicrobial process, and reported their findings in <em>Molecular Cell</em> on June 4, 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731671</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731671-trim21-marks-viruses-and-bacteria-for-degradation-via-autophagy</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Cellular-autophagy-lysosome-autophagosome.webp?t=1780669642" type="image/jpeg" medium="image" fileSize="618645">
        <media:title type="plain">3D illustration showing fusion of lysosome with autophagosome containing microbes and molecules</media:title>
        <media:description type="plain">Autophagy</media:description>
      </media:content>
    </item>
    <item>
      <title>Dual PPARδ/α agonists reported in Shenzhen Hightide Biotechnology patent</title>
      <description>
        <![CDATA[Shenzhen Hightide Biopharmaceutical Ltd. has identified new peroxisome proliferator-activated receptor δ (PPARδ) and PPARα dual agonists potentially useful for the treatment of obesity, aging, cardiovascular disorders, heart failure, inflammatory disorders, metabolic dysfunction-associated steatotic liver disease (MASLD; NAFLD), metabolic syndrome and renal failure.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731667</guid>
      <pubDate>Thu, 04 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731667-dual-ppar-agonists-reported-in-shenzhen-hightide-biotechnology-patent</link>
    </item>
    <item>
      <title>Pfizer patents new PI3Kα mutant inhibitors</title>
      <description>
        <![CDATA[Pfizer Inc. has reported new biaryl acid compounds acting as phosphatidylinositol 3-kinase α (PI3Kα) H1047R mutant inhibitors potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731666</guid>
      <pubDate>Thu, 04 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731666-pfizer-patents-new-pi3k-mutant-inhibitors</link>
    </item>
    <item>
      <title>Bial-Portela discovers new OX1 receptor antagonists</title>
      <description>
        <![CDATA[Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders, schizophrenia, obesity, sleep disorders, post-traumatic stress, substance abuse and dependence, among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731665</guid>
      <pubDate>Thu, 04 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731665-bial-portela-discovers-new-ox1-receptor-antagonists</link>
    </item>
  </channel>
</rss>
